Welcome to our dedicated page for COLGATE PALMOLIVE CO SEC filings (Ticker: CL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Colgate-Palmolive Company filings document a global consumer-products issuer with NYSE-listed common stock and registered debt securities. The company's 8-K reports cover earnings releases, the Strategic Growth and Productivity Program, reportable operating segment realignments, senior-note activity, debt-listing changes and governance events such as director elections and officer succession.
Proxy materials describe board elections, executive compensation, shareholder voting matters and strategic priorities tied to growth, efficiency and cash flow. The filings also identify registered securities, including common stock and multiple note series, and provide formal records for shareholder meetings, compensation arrangements and changes affecting listed note classes.
Colgate-Palmolive director Harris C. Martin received new equity awards. On May 11, 2026, he was granted 1,556 shares of Common Stock as an annual director stock grant under the company’s incentive compensation plan.
He was also granted stock options for 2,424 shares of Common Stock with an exercise price of $86.74 per share, expiring on May 11, 2034. These options become exercisable in equal annual installments over three years beginning on the first anniversary of the grant date. Following the stock grant, he directly holds 24,517 common shares, plus the newly granted options.
Colgate-Palmolive director Lisa Edwards received routine equity awards as part of her compensation. She was granted 2,075 shares of common stock and 2,424 stock options on May 11, 2026 under the company’s incentive compensation plan. After the grant, she directly owns 18,182 common shares.
The options allow her to buy 2,424 common shares at an exercise price of $86.74 per share and expire on May 11, 2034. They become exercisable in equal annual installments over three years, starting on the first anniversary of the grant date.
COLGATE PALMOLIVE CO director John T. Cahill reported routine equity compensation awards. On May 11, 2026, he received an annual director stock grant of 2,075 shares of common stock, increasing his directly held shares to 28,216.
He also received an annual director stock option grant for 2,424 shares of common stock at a conversion price of $86.74 per share, with options vesting in equal annual installments over three years beginning on the first anniversary of the grant date and expiring on May 11, 2034. Separately, 36,357 shares are reported as held indirectly through a trust, which includes 2,019 shares previously reported as directly owned.
Colgate-Palmolive director Christopher S. Boerner reported equity compensation awards. He received an annual director stock grant of 1,383 shares of common stock under the company’s incentive compensation plan, leaving him with 1,383 common shares directly owned after the award.
He was also granted a stock option for 2,020 shares of common stock with an exercise price of $86.74 per share, expiring on May 11, 2034. The option becomes exercisable in equal annual installments over three years, beginning on the first anniversary of the May 11, 2026 grant date. These are compensation-related awards rather than open-market purchases or sales.
COLGATE PALMOLIVE CO director John P. Bilbrey reported routine equity compensation and updated holdings. He received a grant of 2,075 shares of Common Stock as an annual director stock grant under the issuer's incentive compensation plan, increasing his direct holdings to 39,820 shares. He also received an annual director stock option grant for 2,424 shares at an exercise price of $86.74 per share, expiring on May 11, 2034, which becomes exercisable in equal annual installments over three years beginning on the first anniversary of the May 11, 2026 grant date. In addition, a separate entry reflects 4,719 shares of Common Stock held indirectly by a trust.
Colgate-Palmolive Company held its Annual Meeting of Stockholders on May 8, 2026. Stockholders elected ten directors, including Noel Wallace and nine other nominees, each receiving several hundred million votes in favor, with broker non-votes recorded on the election items.
Stockholders ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, with 647,385,500 votes for and 53,015,911 against. A non-binding advisory vote on executive compensation was approved, with 591,185,556 votes for and 43,039,011 against.
Two stockholder proposals were not approved. A proposal titled “Remove DEI from Board Candidate Considerations” received 14,002,273 votes for and 618,251,142 against. A proposal titled “Independent Board Chairman” received 182,439,869 votes for and 452,415,385 against.
Colgate-Palmolive Chief People Officer Sally Massey sold 8,599 shares of Common Stock in an open-market transaction. The sale took place on May 7, 2026 at a weighted average price of $87.4093 per share, with individual prices ranging from $87.36 to $87.53.
After the sale, Massey directly owned 13,785 shares of Colgate-Palmolive common stock and indirectly held 8,152 shares through the issuer’s 401(k) plan trustee.
Colgate-Palmolive Company reported first-quarter 2026 Net sales of $5,324 million, up 8.4% from 2025, driven by 1.1% volume growth, 2.2% higher pricing and 5.1% positive foreign exchange. Organic sales grew 2.9%, with Oral, Personal and Home Care organic sales up 3.1% and Hill’s Pet Nutrition up 2.1%.
Gross profit rose to $3,226 million, though gross margin slipped to 60.6% as significantly higher raw and packaging material costs more than offset funding-the-growth savings and pricing. GAAP operating profit fell to $964 million, but on a non-GAAP basis increased 4% to $1,134 million, reflecting restructuring adjustments.
GAAP diluted EPS declined to $0.80 from $0.85, while non-GAAP diluted EPS increased to $0.97 from $0.91, helped by higher operating profit and share count changes. The Board expanded the Strategic Growth and Productivity Program, raising expected cumulative pre-tax charges to $350–$550 million and targeting annualized pre-tax savings of $200–$300 million by the end of 2028.
Colgate-Palmolive Company reported mixed first quarter 2026 results and expanded its Strategic Growth and Productivity Program. Net sales rose to $5,324 million, up 8.4% from $4,911 million, with organic sales up 2.9%. GAAP diluted EPS declined 6% to $0.80, while Base Business diluted EPS increased 7% to $0.97. Operating profit on a GAAP basis fell 10% to $964 million, but Base Business operating profit grew 4% to $1,134 million. Net cash provided by operations was $747 million, producing free cash flow before dividends of $609 million.
The Board approved an expansion of the Strategic Growth and Productivity Program, now expected to generate cumulative pre-tax charges of $350 million to $550 million, up from $200 million to $300 million, with 80% to 90% of these charges in cash and substantially all incurred by December 31, 2028. The program targets organizational changes and supply chain optimization across all regions and businesses. Colgate maintained its 2026 sales and EPS guidance but now expects gross profit margin to be down on both GAAP and Base Business bases.
Colgate-Palmolive Co reports a 13G filing showing 60,404,276 shares beneficially owned (7.52% of the class). The filing states Vanguard Capital Management has sole voting power for 8,184,452 shares and sole dispositive power for 60,404,276 shares.
The filing notes these holdings are reported on behalf of Vanguard-managed funds and accounts under Schedule 13G and were signed on 04/29/2026.